Benign recurrent intrahepatic cholestasis type 1
bee-nine ree-kur-ent in-tra-heh-pa-tik koh-les-ta-sis type one
Also known as: BRIC1, Summerskill-Walshe-Tygstrup syndrome
At a Glance
What is Benign recurrent intrahepatic cholestasis type 1?
Benign recurrent intrahepatic cholestasis type 1 is a rare liver disorder that causes episodes of jaundice and itching due to impaired bile flow. It primarily affects the liver but can also impact the skin and digestive system. The condition is caused by mutations in the ATP8B1 gene, which disrupts the normal function of liver cells. Symptoms typically begin in childhood or early adulthood and can include jaundice, itching, and fatigue. Early symptoms are often mild but can become more severe over time, leading to significant discomfort. Early diagnosis is crucial to managing symptoms and preventing complications. The condition can be challenging for families due to its unpredictable nature and the need for ongoing medical care. Prognosis is generally good, as the condition does not lead to liver failure, but it can significantly impact quality of life. Daily life for affected individuals may involve managing symptoms with medications and lifestyle adjustments. Although the disorder is lifelong, episodes of cholestasis are usually self-limiting. With appropriate management, individuals can lead relatively normal lives. Support from healthcare providers and patient communities can be invaluable for affected families.
Medical Definition
Benign recurrent intrahepatic cholestasis type 1 is a genetic disorder characterized by episodes of cholestasis without progression to liver failure. It is caused by mutations in the ATP8B1 gene, leading to impaired bile acid transport and accumulation within the liver. Histologically, the liver shows canalicular cholestasis without significant inflammation or fibrosis. The condition is classified under progressive familial intrahepatic cholestasis disorders but is distinguished by its benign course. Epidemiologically, it is a rare disorder with a prevalence of approximately 1 in 100,000 individuals. The disease course involves recurrent episodes of cholestasis that resolve spontaneously, with patients remaining asymptomatic between episodes.
Benign recurrent intrahepatic cholestasis type 1 Symptoms
Symptoms vary in severity between individuals. Early diagnosis and management can significantly improve outcomes.
Very Common
Pruritus manifests as an intense itching sensation that can be widespread or localized. It is caused by the accumulation of bile acids in the bloodstream due to impaired bile flow. Over time, pruritus can become more severe and persistent, leading to significant discomfort. It affects daily life by disrupting sleep and concentration, and antihistamines or bile acid sequestrants can provide relief.
Jaundice presents as a yellowing of the skin and eyes due to elevated bilirubin levels. This occurs when the liver's ability to process bilirubin is impaired, leading to its accumulation in the blood. The intensity of jaundice can fluctuate, often correlating with the severity of cholestatic episodes. It can affect self-esteem and social interactions, and management includes addressing the underlying cholestasis.
Fatigue is characterized by a persistent feeling of tiredness and lack of energy. It results from the body's increased metabolic demand and the liver's reduced efficiency in detoxifying the blood. Fatigue can worsen during cholestatic episodes and may persist even during remission. It impacts daily activities and productivity, and lifestyle modifications along with adequate rest are recommended.
Common
Abdominal pain is often experienced as a dull or sharp discomfort in the upper right quadrant of the abdomen. It is caused by liver enlargement or inflammation due to bile accumulation. The pain may come and go, often worsening during cholestatic episodes. It can limit physical activities and may require analgesics for management.
Nausea is a sensation of unease and discomfort in the stomach, often leading to vomiting. It is triggered by the buildup of toxins and bile acids in the bloodstream. Nausea can be intermittent or persistent, particularly during acute episodes. It affects appetite and nutritional intake, and antiemetics may be prescribed for relief.
Dark urine is a noticeable change in urine color, often appearing tea-colored. This occurs due to increased excretion of bilirubin in the urine when it cannot be adequately processed by the liver. The condition may fluctuate, aligning with the severity of jaundice. It can be alarming to patients, prompting medical consultation, and is managed by treating the underlying liver dysfunction.
Less Common
Steatorrhea is the presence of excess fat in stools, making them bulky and foul-smelling. It results from the liver's impaired ability to secrete bile acids necessary for fat digestion. This symptom may be episodic, often coinciding with periods of cholestasis. It can lead to malnutrition and weight loss, and dietary adjustments along with enzyme supplements may be beneficial.
Hepatomegaly is the enlargement of the liver, detectable through physical examination or imaging. It occurs due to the accumulation of bile and subsequent liver inflammation. The enlargement may persist or resolve depending on the disease's activity. It may cause discomfort and pressure in the abdomen, and monitoring liver function is essential for management.
What Causes Benign recurrent intrahepatic cholestasis type 1?
Benign recurrent intrahepatic cholestasis type 1 is primarily caused by mutations in the ATP8B1 gene, located on chromosome 18q21. The ATP8B1 gene encodes a protein known as FIC1, which is an aminophospholipid translocase involved in maintaining the asymmetric distribution of phospholipids across the canalicular membrane of hepatocytes. Mutations in ATP8B1 can lead to the production of a truncated or misfolded FIC1 protein, disrupting its normal function. This disruption impairs the translocation of phosphatidylserine and phosphatidylethanolamine, leading to abnormal bile composition and impaired bile flow. The accumulation of bile acids within hepatocytes can cause cellular stress and damage, triggering an inflammatory response. This inflammation can extend to neighboring liver cells, exacerbating liver dysfunction and contributing to the cholestatic episodes characteristic of the disease. Although neuroinflammation is not a primary feature, systemic inflammation can indirectly affect neural tissues. The degeneration of liver cells and potential systemic effects can lead to the episodic nature of symptoms, with periods of remission and exacerbation. The variability in disease severity among patients is influenced by the specific type and location of the ATP8B1 mutation, as well as other genetic and environmental factors. The episodic pattern of symptoms is due to the liver's fluctuating ability to manage bile acid levels and inflammation. Some patients may experience more severe symptoms due to additional genetic mutations or environmental triggers that exacerbate the underlying defect. The immune response to the cellular damage can further contribute to symptom variability, as individual immune system differences can alter the inflammatory response. The episodic cholestasis can lead to progressive liver damage if not managed, although it is typically non-progressive. Understanding the precise molecular mechanisms can help in developing targeted therapies to manage or prevent the episodes.
How is Benign recurrent intrahepatic cholestasis type 1 Diagnosed?
Typical age of diagnosis: Benign recurrent intrahepatic cholestasis type 1 is typically diagnosed in childhood or early adulthood when patients present with recurrent episodes of jaundice and pruritus, often triggered by stress or infections.
Clinicians look for recurrent episodes of jaundice and pruritus without permanent liver damage. A detailed patient history is crucial, focusing on the frequency and triggers of symptoms. Physical examination may reveal jaundice and scratch marks due to pruritus. This step helps differentiate BRIC1 from other liver diseases with progressive liver damage.
Ultrasound is commonly used to assess liver structure and exclude biliary obstruction. Imaging typically shows normal liver architecture without evidence of cirrhosis. These findings support the diagnosis of BRIC1 by ruling out obstructive causes of cholestasis. Differential diagnoses like primary sclerosing cholangitis are excluded based on imaging results.
Liver function tests are ordered to assess bilirubin and alkaline phosphatase levels. Elevated bilirubin and alkaline phosphatase with normal gamma-glutamyl transferase are indicative. These abnormal results suggest intrahepatic cholestasis and guide further genetic testing. Additional tests may include serum bile acids to confirm cholestasis.
Genetic testing involves sequencing the ATP8B1 gene. Nonsense or missense mutations in ATP8B1 confirm the diagnosis of BRIC1. Results provide definitive diagnosis and inform genetic counseling for the family. Identifying mutations helps predict disease course and recurrence risk in relatives.
Benign recurrent intrahepatic cholestasis type 1 Treatment Options
Colestyramine is a bile acid sequestrant used to reduce pruritus. It works by binding bile acids in the intestine, preventing reabsorption. Clinical evidence shows it can alleviate symptoms in BRIC1 patients. Limitations include gastrointestinal side effects like bloating and constipation. Its efficacy may vary, and it does not prevent recurrence of cholestatic episodes.
Techniques include skin hydration and topical treatments to reduce itching. The goal is to alleviate discomfort and improve quality of life. Sessions may be recommended weekly during symptomatic periods. Measurable outcomes include reduced pruritus severity and improved sleep. Long-term benefits include enhanced skin integrity and patient comfort.
Indicated in cases of severe, refractory cholestasis with significant quality of life impact. The procedure involves replacing the diseased liver with a healthy donor liver. Expected benefits include resolution of cholestasis and symptom relief. Surgical risks include rejection and complications from immunosuppression. Post-operative care involves lifelong monitoring and medication adherence.
The team includes hepatologists, genetic counselors, and dietitians. Interventions focus on symptom management, nutritional support, and genetic counseling. Psychosocial support strategies address emotional and mental health needs. Family education covers disease management and genetic implications. Long-term monitoring includes regular follow-ups to assess liver function and manage complications.
When to See a Doctor for Benign recurrent intrahepatic cholestasis type 1
- Severe jaundice — indicates significant liver dysfunction requiring immediate medical attention.
- Intense abdominal pain — could signify a serious complication such as liver inflammation or obstruction.
- Confusion or altered mental state — may indicate hepatic encephalopathy, a potentially life-threatening condition.
- Persistent itching — may suggest worsening liver function and should be evaluated by a healthcare provider.
- Dark urine or pale stools — could indicate bile flow obstruction and warrants further investigation.
- Unexplained weight loss — may be a sign of malabsorption or other underlying issues needing medical evaluation.
- Mild fatigue — monitor energy levels and maintain a balanced diet; consult a doctor if it worsens.
- Occasional nausea — keep track of frequency and triggers; seek medical advice if it becomes persistent.
Benign recurrent intrahepatic cholestasis type 1 — Frequently Asked Questions
Is this condition hereditary?
Benign recurrent intrahepatic cholestasis type 1 is inherited in an autosomal recessive pattern. This means both parents must be carriers for a child to be affected, with a 25% chance of passing it to offspring. De novo mutations are rare but possible. Carrier status does not typically cause symptoms but can be significant for family planning. Genetic counseling is recommended for affected families to understand risks and options.
What is the life expectancy for someone with this condition?
Life expectancy is generally normal, although quality of life may be affected by recurrent episodes. Early onset may lead to more frequent attacks, impacting overall health. Mortality is rare and usually related to complications like liver failure. Effective management and treatment can improve outcomes and reduce episode frequency. Patients should have realistic expectations about managing symptoms rather than curing the condition.
How is this condition diagnosed and how long does diagnosis take?
Diagnosis involves genetic testing for ATP8B1 mutations, liver function tests, and clinical evaluation. It can take months to years from symptom onset to diagnosis due to its rarity and symptom overlap with other liver diseases. Gastroenterologists and geneticists are typically involved in the diagnostic process. Delays often occur due to misdiagnosis or lack of awareness among healthcare providers. Confirmation is achieved through genetic testing and exclusion of other conditions.
Are there any new treatments or clinical trials available?
Research is ongoing, with promising studies on gene therapy and novel pharmacological treatments. Clinical trials can be found on ClinicalTrials.gov by searching for 'benign recurrent intrahepatic cholestasis type 1'. Patients should discuss potential trial participation with their doctor. New treatments are in early stages, so availability may take several years. Staying informed through medical updates and research publications is recommended.
How does this condition affect daily life and activities?
Daily life can be impacted by fatigue and itching, affecting mobility and self-care. Educational performance may suffer during episodes due to concentration difficulties. Social and emotional challenges include coping with chronic illness and potential stigma. Family members may face caregiving burdens and emotional stress. Supportive therapies and adaptations, such as flexible schedules and counseling, can help manage these challenges.
Learn More
Support & Resources
References
Content generated with support from peer-reviewed literature via PubMed.
- 1.Benign Recurrent Intrahepatic Cholestasis Type 1 with Novel Nonsense Mutations in the ATP8B1 Gene.
Miura R, Kawaoka T, Imamura M et al. · Case Rep Gastroenterol · 2022 · PMID: 35431768
- 2.Benign Recurrent Intrahepatic Cholestasis Type 1 with Novel Gene Mutation Complicated by Distal Renal Tubular Acidosis: A Case Report.
Vo VH, Nguyen CD, Phan ST et al. · Case Rep Gastroenterol · 2025 · PMID: 40880677
- 3.Differential effects of progressive familial intrahepatic cholestasis type 1 and benign recurrent intrahepatic cholestasis type 1 mutations on canalicular localization of ATP8B1.
Folmer DE, van der Mark VA, Ho-Mok KS et al. · Hepatology · 2009 · PMID: 19731236
- 4.Case Report: A Rare Case of Benign Recurrent Intrahepatic Cholestasis-Type 1 With a Novel Heterozygous Pathogenic Variant of ATP8B1.
Suzuki H, Arinaga-Hino T, Sano T et al. · Front Med (Lausanne) · 2022 · PMID: 35572954
- 5.Case Report: A Novel Homozygous Variant Identified in a Chinese Patient With Benign Recurrent Intrahepatic Cholestasis-Type 1.
Chen H, Wu D, Jiang W et al. · Front Med (Lausanne) · 2021 · PMID: 34485338
- 6.Long-Term Colestyramine Treatment Prevents Cholestatic Attacks in Refractory Benign Recurrent Intrahepatic Cholestasis Type 1 Disease.
Koukoulioti E, Ziagaki A, Weber SN et al. · Hepatology · 2021 · PMID: 33277690
- 7.Enigmatic functions of ATP8B1: cholestasis, inflammation, phosphoinositide flipping, and cellular homeostasis.
Prince A, Traughber CA, Shiravand Y et al. · Cell Cycle · 2025 · PMID: 41084973
- 8.Successful treatment of a patient with benign recurrent intrahepatic cholestasis type 1 with albumin dialysis.
Schoeneich K, Frimmel S, Koball S · Artif Organs · 2020 · PMID: 31642075
This content is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.Last reviewed: 2026-06-14